A Pathway for Necrotic Cell Death
坏死细胞死亡的途径
基本信息
- 批准号:10680459
- 负责人:
- 金额:$ 37.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-09 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:Antineoplastic AgentsApoptosisApoptosis PromoterAutophagocytosisBrainBreast Cancer CellBreast cancer metastasisCRISPR screenCalciumCell Culture TechniquesCell DeathCell Death InductionCell Death InhibitionCell LineCell membraneCellsCessation of lifeClinicalClinical TrialsColonColon CarcinomaDataDevelopmentDiapauseDisseminated Malignant NeoplasmDrug TargetingElectroporationEmbryoEndometrial CarcinomaEstrogen Receptor alphaEstrogensGoalsImmuneImmune checkpoint inhibitorImmunocompromised HostImmunotherapeutic agentImmunotherapyKnock-outKnowledgeLinkMYC Family ProteinMalignant NeoplasmsMalignant neoplasm of ovaryMammary NeoplasmsMediatingMediatorMembraneMetastatic Neoplasm to the BoneMetastatic Neoplasm to the LiverMetastatic Neoplasm to the LungMetastatic malignant neoplasm to brainMitochondriaMusNecrosisNecrosis InductionNeoplasm MetastasisOncolyticOsmosisPathway interactionsPatientsPeptidesPharmaceutical PreparationsProtein Synthesis InhibitionProteinsRecurrenceRegulatory PathwayResistanceRetreatmentRuptureSodium ChannelStressSwellingTestingTherapeuticTumor MarkersUterusWaterWorkXenograft ModelXenograft procedurecancer cellcancer immunotherapycancer therapycancer typedrug developmentendoplasmic reticulum stressflexibilitygenome-wideimmunogenicimmunogenic cell deathmalignant ascitesmalignant breast neoplasmmouse modelneoantigensnovel anticancer drugnovel therapeuticsprotein biomarkersprotein foldingproteostasisreceptorresistance mechanismresponsesensorsuccesstargeted agenttherapeutic targettherapy resistanttranscriptome sequencingtriple-negative invasive breast carcinomatumorvirtual
项目摘要
Unlike other death pathways, protein mediators of drug-induced necrotic cell death were poorly defined.
Necrosis activates immune cells, inducing immunogenic cell death. Therefore, understanding necrosis
provides new avenues for enhancing drug development and cancer immunotherapy. Our anticancer drugs
BHPI and ErSO act via estrogen receptor α (ERα) to induce lethal necrosis-inducing hyperactivation of the
anticipatory Unfolded Protein Response (a-UPR). In orthotopic xenografts and a PDX, ErSO eradicates
primary and metastatic therapy-resistant ERα+ breast cancer, induces near complete regression of lethal
breast cancer in brain, and of endometrial cancer and ovarian cancer, and kills most ovarian cancer cells in
patient malignant ascites. From CRISPR screens against BHPI and ErSO, we identified the Ca2+ activated,
plasma membrane Na+ channel TRPM4 as the executioner protein that BHPI and ErSO use to induce
necrosis and the likely membrane flexibility modulator FGD3. BHPI and ErSO-induced elevated Ca2+ opens
the TRPM4 channel, eliciting a rapid influx of external Na+, Cl- and accompanying water. This swells the
cells, causing osmotic stress, which hyperactivates the UPR, leading to ATP depletion, FGD3 enhanced
membrane rupture and necrotic cell death. TRPM4 knockout abolished ATP depletion, sustained UPR
hyperactivation, cell swelling and death. Notably, TRPM4 knockout also inhibited necrosis induced by
unrelated anticancer therapies, the mitochondrial targeting oncolytic peptide, LTX-315, the Ca2+ channel
targeting agent, Englerin A and Ca2+ electroporation (CaEP). Aim 1. Identify and functionally characterize
known and additional shared components of the TRPM4 pathway. We will combine data from completed
CRISPR screens, new screens using LTX-315, Englerin A, and CaEP and RNA-seq data from our recently
developed ErSO resistant cell lines. Aim 2. Using cell and tumor studies, test the hypothesis that diverse
necrosis-inducing anticancer therapies, in which Ca2+ levels are increased by transient a-UPR activation or
other mechanisms, share a common pathway that converges on the UPR-TRPM4-FGD3 pathway. To
extend UPR activation therapies to ERα- cancers, test the idea that the clinically promising, mechanistically
obscure, necrosis-inducing therapy, Ca2+ electroporation, works in part through the UPR-TRPM4-FGD3
necrosis pathway. Aim 3. Using syngeneic mouse models establish whether necrosis-inducing agents
extend the reach of immunotherapy to rapidly lethal breast cancer that has metastasized to brain and does
not express neoantigens. Aim 4. Mechanisms of resistance to necrosis inducing cancer drugs are largely
unexplored. Using our Myc down-regulated reversibly quiescent cells, we will identify ErSO resistance
mechanisms and test whether loss of Myc in the quiescent cells is due to a-UPR mediated ATP depletion
activating AMPK, thereby inhibiting protein synthesis via eEF2. These studies will establish a new
pathway of immunogenic anticancer therapy-induced necrotic cell death through the UPR.
与其他死亡途径不同,药物诱导的坏死性细胞死亡的蛋白质介体的定义不明确。
坏死激活免疫细胞,诱导免疫原性细胞死亡。因此,认识坏死
为加强药物开发和癌症免疫治疗提供了新的途径。我们的抗癌药物
BHPI和ERSO通过雌激素受体α(ERα)诱导致死性坏死诱导的细胞过度激活
预期未折叠蛋白反应(a-UPR)。在异种原位移植和PDX中,ERSO被根除
原发和转移耐药ERα+乳腺癌,导致致命性近乎完全消退
脑部乳腺癌,子宫内膜癌和卵巢癌,并杀死大多数卵巢癌细胞在
病人恶性腹水。从抗BHPI和ERSO的CRISPR筛选中,我们鉴定了钙激活的,
质膜Na+通道TRPM4作为BHPI和ERSO诱导的执行者蛋白
坏死和可能的膜弹性调节剂FGD3。BHPI和ERSO诱导的钙离子开放
TRPM4通道,引发外部Na+、Cl-和伴随水的快速内流。这扩大了
细胞,导致渗透应激,从而过度激活UPR,导致ATP耗竭,FGD3增强
胎膜破裂和坏死细胞死亡。TRPM4基因敲除消除了ATP耗竭,持续了UPR
过度活跃,细胞肿胀和死亡。值得注意的是,TRPM4基因敲除也抑制了由
无关的抗癌治疗,线粒体靶向溶瘤多肽LTX-315,钙通道
靶向剂、恩格列菌素A和钙离子电穿孔(CAEP)。目标1.确定并确定功能特征
TRPM4途径的已知和其他共享组件。我们将合并来自Complete的数据
CRISPR屏幕,使用LTX-315、Engerin A和CAEP以及来自我们最近的RNA-SEQ数据的新屏幕
开发了耐ERSO的细胞系。目标2.使用细胞和肿瘤研究,检验不同的假设
诱导坏死的抗癌治疗,其中钙离子水平通过短暂的a-UPR激活或
其他机制共享一个共同的通路,该通路汇聚在UPR-TRPM4-FGD3通路上。至
将UPR激活疗法扩展到ER-α癌症,测试临床上有希望的,机械性的
晦涩难懂的坏死诱导疗法,钙离子电穿孔,部分通过UPR-TRPM4-FGD3发挥作用
坏死途径。目的3.利用同基因小鼠模型建立坏死诱导剂
将免疫治疗的范围扩大到迅速致命的乳腺癌,这种乳腺癌已经转移到脑内,并
不表达新抗原。目的4.抗坏死致癌药物的机制主要是
未被开发的。利用我们的Myc下调的可逆静止细胞,我们将鉴定ERSO抗性
静止期细胞Myc丢失的机制及检测是否与a-UPR介导的ATP耗竭有关
激活AMPK,从而抑制通过eEF2的蛋白质合成。这些研究将建立一个新的
免疫原性抗癌治疗通过UPR诱导坏死细胞死亡的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID J SHAPIRO其他文献
DAVID J SHAPIRO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID J SHAPIRO', 18)}}的其他基金
Targeting c-Myc and MDR1 in Cancer Through Small Molecule Inhibitors of IMP-1
通过 IMP-1 小分子抑制剂靶向癌症中的 c-Myc 和 MDR1
- 批准号:
8688973 - 财政年份:2013
- 资助金额:
$ 37.89万 - 项目类别:
Targeting c-Myc and MDR1 in Cancer Through Small Molecule Inhibitors of IMP-1
通过 IMP-1 小分子抑制剂靶向癌症中的 c-Myc 和 MDR1
- 批准号:
8584046 - 财政年份:2013
- 资助金额:
$ 37.89万 - 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
- 批准号:
8448699 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
- 批准号:
7655786 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
- 批准号:
8052823 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
How Rapid Anticipatory Estrogen Activation of the Unfolded Protein Response Acts as an Authorizing Signal for Estrogen Receptor Action
未折叠蛋白反应的快速预期雌激素激活如何作为雌激素受体作用的授权信号
- 批准号:
9294047 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
How Rapid Anticipatory Estrogen Activation of the Unfolded Protein Response Acts as an Authorizing Signal for Estrogen Receptor Action
未折叠蛋白反应的快速预期雌激素激活如何作为雌激素受体作用的授权信号
- 批准号:
9915884 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
Assays for Estogen and Progesterone Receptor Antagonists
雌激素和孕激素受体拮抗剂的测定
- 批准号:
7094064 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
Targeting Breast Cancer with Small Molecule Inhibitors of Estrogen Receptor
用雌激素受体小分子抑制剂治疗乳腺癌
- 批准号:
8247814 - 财政年份:2005
- 资助金额:
$ 37.89万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 37.89万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 37.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 37.89万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 37.89万 - 项目类别:
Discovery Grants Program - Individual